ESR1 and triple-negative breast carcinoma: Studies have shown the high sensitivity of TRPS1 in estrogen receptor (ER)-positive (98%), human epidermal growth factor receptor 2 (HER2neu)-positive (87%), and triple negative breast cancer (TNBC) (86%), which is higher than other breast markers, including GATA3 [5].